Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug;100(8):2105-2106.
doi: 10.1007/s00277-021-04557-1. Epub 2021 May 18.

Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders

Laura Herbreteau  1 , Ronan Le Calloch  2 , Bertrand Arnaud  3 , Nicolas Cassou  4 , Marie-Jeanne Rizcallah  2 , Pascal Hutin  2 , Lenaïg Le Clech  2
Affiliations
Case Reports

Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders

Laura Herbreteau et al. Ann Hematol. 2021 Aug.
No abstract available

PubMed Disclaimer

References

    1. Swiecicki PL, Hegerova LT, Gertz MA (2013) Cold agglutinin disease. Blood 122:1114–1121. https://doi.org/10.1182/blood-2013-02-474437 - DOI - PubMed
    1. Berentsen S et al (2010) High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 116:3180–3184. https://doi.org/10.1182/blood-2010-06-288647 - DOI - PubMed
    1. Berentsen S et al (2017) Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 130:537–541. https://doi.org/10.1182/blood-2017-04-778175 - DOI - PubMed
    1. Berentsen S (2018) How I manage patients with cold agglutinin disease. Br J Haematol 181:320–330. https://doi.org/10.1111/bjh.15109 - DOI - PubMed
    1. Röth A, Hüttmann A, Rother RP, Dührsen U, Philipp T (2009) Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113:3885–3886. https://doi.org/10.1182/blood-2009-01-196329 - DOI - PubMed

MeSH terms

LinkOut - more resources